AU2006233567A1 - Therapeutic combination in case of benign prostate hyperplasia - Google Patents

Therapeutic combination in case of benign prostate hyperplasia Download PDF

Info

Publication number
AU2006233567A1
AU2006233567A1 AU2006233567A AU2006233567A AU2006233567A1 AU 2006233567 A1 AU2006233567 A1 AU 2006233567A1 AU 2006233567 A AU2006233567 A AU 2006233567A AU 2006233567 A AU2006233567 A AU 2006233567A AU 2006233567 A1 AU2006233567 A1 AU 2006233567A1
Authority
AU
Australia
Prior art keywords
inhibitor
pde
release
controlled
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006233567A
Other languages
English (en)
Inventor
Erwin Bischoff
Helmut Haning
Peter Serno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of AU2006233567A1 publication Critical patent/AU2006233567A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2006233567A 2005-04-13 2006-03-31 Therapeutic combination in case of benign prostate hyperplasia Abandoned AU2006233567A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (de) 2005-04-13 2005-04-13 Kombination zur Therapie bei benigner Prostatahyperplasie
DE102005016981.3 2005-04-13
PCT/EP2006/002941 WO2006108519A1 (de) 2005-04-13 2006-03-31 Kombination zur therapie bei benigner prostatahyperplasie

Publications (1)

Publication Number Publication Date
AU2006233567A1 true AU2006233567A1 (en) 2006-10-19

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006233567A Abandoned AU2006233567A1 (en) 2005-04-13 2006-03-31 Therapeutic combination in case of benign prostate hyperplasia

Country Status (22)

Country Link
EP (1) EP1888075A1 (zh)
JP (1) JP2008535877A (zh)
KR (1) KR20080007252A (zh)
CN (1) CN101193638A (zh)
AR (1) AR053575A1 (zh)
AU (1) AU2006233567A1 (zh)
BR (1) BRPI0610634A2 (zh)
CA (1) CA2605224A1 (zh)
CR (1) CR9427A (zh)
DE (1) DE102005016981A1 (zh)
DO (1) DOP2006000074A (zh)
GT (1) GT200600145A (zh)
IL (1) IL186604A0 (zh)
MA (1) MA29683B1 (zh)
MX (1) MX2007012567A (zh)
PE (1) PE20061338A1 (zh)
RU (1) RU2007141518A (zh)
SV (1) SV2008002477A (zh)
TN (1) TNSN07385A1 (zh)
TW (1) TW200716122A (zh)
UY (1) UY29473A1 (zh)
WO (1) WO2006108519A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074464A3 (en) * 2017-10-09 2019-05-31 Montero Gida Sanayi Ve Ticaret Anonim Sirketi The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
CA2633570A1 (en) * 2005-12-21 2007-06-28 Pfizer Products Inc. Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
MX2008016569A (es) * 2006-07-07 2009-01-30 Teva Pharma Composiciones solidas que contienen tadalafil y al menos un portador.
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
PL2222300T3 (pl) 2007-12-13 2015-02-27 Vanda Pharmaceuticals Inc Sposób i skład preparatu do leczenia chorób z udziałem receptorów serotoniny
CA2709103C (en) 2007-12-13 2017-01-17 Vanda Pharmaceuticals Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
US8885621B2 (en) 2010-04-26 2014-11-11 Intel Corporation Method, apparatus and system for switching traffic streams among multiple bands
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
RU2672573C2 (ru) * 2013-06-28 2018-11-16 Ханми Фарм. Ко., Лтд. Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
KR20240015735A (ko) 2013-07-23 2024-02-05 세레니티 파마슈티컬즈 엘엘씨 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR20150056443A (ko) * 2013-11-15 2015-05-26 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합제제
EP3150201B1 (en) * 2014-06-30 2020-02-19 Hanmi Pharm. Co., Ltd. Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation
WO2016003180A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
BR112016030731A2 (pt) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd Preparação de compósito, e, método de preparação de uma preparação de compósito
KR20240010751A (ko) * 2014-11-20 2024-01-24 세레니티 파마슈티컬즈 엘엘씨 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
US20190125685A1 (en) * 2016-03-31 2019-05-02 Hanmi Pharm. Co., Ltd. Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate
KR101835506B1 (ko) * 2016-10-25 2018-03-07 주식회사 에스텍파마 두타스테리드와 타다라필을 함유하는 속효성 복합정제
CN108066347B (zh) * 2016-11-16 2021-02-02 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019074464A3 (en) * 2017-10-09 2019-05-31 Montero Gida Sanayi Ve Ticaret Anonim Sirketi The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Also Published As

Publication number Publication date
IL186604A0 (en) 2008-01-20
AR053575A1 (es) 2007-05-09
GT200600145A (es) 2007-04-10
MX2007012567A (es) 2007-12-10
EP1888075A1 (de) 2008-02-20
RU2007141518A (ru) 2009-05-20
MA29683B1 (fr) 2008-08-01
TW200716122A (en) 2007-05-01
DE102005016981A1 (de) 2006-10-19
DOP2006000074A (es) 2006-10-15
SV2008002477A (es) 2008-02-08
PE20061338A1 (es) 2007-01-28
BRPI0610634A2 (pt) 2010-07-13
TNSN07385A1 (en) 2009-03-17
WO2006108519A1 (de) 2006-10-19
CN101193638A (zh) 2008-06-04
UY29473A1 (es) 2006-11-30
CR9427A (es) 2007-12-17
CA2605224A1 (en) 2006-10-19
KR20080007252A (ko) 2008-01-17
JP2008535877A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
AU2006233567A1 (en) Therapeutic combination in case of benign prostate hyperplasia
RU2504362C2 (ru) Системы доставки лекарственных веществ, включающие в себя слабоосновные лекарственные вещества и органические кислоты
JP2018162255A (ja) デフェラシロクスの経口製剤
US20210322429A1 (en) Stabilized formulations of cns compounds
CA2529746A1 (en) Oral extended-release composition
JPH061716A (ja) 活性成分の長期放出性を有する投薬形
JP2010163455A (ja) 活性成分放出制御薬物製剤
US10561602B2 (en) Controlled extended release pregabalin
US20120003307A1 (en) Levetiracetam controlled release composition
EA039091B1 (ru) Фармацевтический комбинированный состав капсулы, содержащий тадалафил и тамсулозин
JP2014193888A (ja) Ｐｐｉ多回剤形
EP3331502B1 (en) Controlled release propiverine formulations
EP4213812A1 (en) Multiparticulate dosage forms comprising deutetrabenazine
WO2003080057A1 (fr) Comprime-noyau de taille reduite contenant de la nifedipine
US20080206338A1 (en) Controlled release formulations of an alpha-adrenergic receptor antagonist
WO2014167439A1 (en) Modified release pharmaceutical compositions of topiramate or salts thereof
TR2023000985A2 (tr) Kontrollü salim sağlayan propi̇veri̇n formülasyonu
WO2009047800A2 (en) Oral controlled release composition of carvedilol
KR20040045485A (ko) 항경련제가 간격을 두고 배치된 약물전달계
MXPA00002929A (en) Medicament formulation with a controlled release of an active agent

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period